Zevra Therapeutics (ZVRA) Following EMA Setback Is The Sell Off A Valuation GapSimplywall·2 hours agoZVRA-23.92%
Navigating Cross-Border Currents: Sector Divergence and Strategic Pivots in a Fragmented 2026 MarketGlobal Report·2 hours agoGNRC-4.03%TGTX+0.97%
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by AnalystsMarket Beat·5 hours agoZVRA-23.92%
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga_article·23 hours agoZVRA-23.92%RADX-17.25%
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union | ZVRA Stock NewsStockTitan·1 day ago, 10:30 PMZVRA-23.92%
Zevra Therapeutics (ZVRA) Following Russell Index Additions Is The Stock Still UndervaluedSimplywall·Jul 2 at 11:57 AMZVRA-23.92%
Zevra Therapeutics Chief Legal & Compliance Rahsaan Thompson sells 34,557 shares for $438,216.86PUBT·Jun 23 at 03:17 PMZVRA-23.92%
